Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.

• Drug: PF-06743649
  
  Daily dosing (dose level 1) tablet for 14 days
• Other: Placebo
  
  Daily dosing (tablet) for 14 days
• Drug: PF-06743649
  
  Daily dosing (dose level 2) tablet(s) for 14 days
• Other: Placebo
  
  Daily dosing (tablets) for 14 days

• Experimental: PF-06743649 dose level 1 (Cohort 1)
  
  Intervention: Drug: PF-06743649
• Placebo Comparator: Placebo for PF-06743649 (Cohort 1)
  
  Intervention: Other: Placebo
• Experimental: PF-06743649 dose level 2 (Cohort 2)
  
  Intervention: Drug: PF-06743649
• Placebo Comparator: Placebo for PF-06743649 (Cohort 2)
  
  Intervention: Other: Placebo

Inclusion Criteria:

• Subject meets the diagnosis of gout as per the American Rheumatism Association Criteria for the Classification of acute Arthritis of Primary Gout.
• Subjects taking urate lowering therapy at the time of screening must be willing to discontinue their prior urate lowering therapy from the time of Screening Visit 1 until completion of the study period Day 16.
• Subjects taking urate lowering therapy at the time of screening must have a serum urate level of >= 8.0 mg/dL at time of the second screening visit.
• Subjects NOT taking urate lowering therapy at the time of screening must have a serum urate level of >= 8.0 mg/dL at both screening visits 1 and 2.

Exclusion Criteria:

• Positive medical history or current evidence of medical or psychiatric condition/disease, or ECG or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
• Chronic kidney disease classified as moderate or severe (Clinical Practice Guideline, National Kidney Foundation)12; with GFR < 60 mL/min/1.73m2 calculated by the Cockcroft-Gault equation.
• Subjects with current tophaceous gout.
• Gout flare that has not resolved for at least 2 weeks prior to randomization.